Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
59.4M
-
Shares change
-
-480K
-
Total reported value, excl. options
-
$78.4M
-
Value change
-
+$883K
-
Put/Call ratio
-
0.62
-
Number of buys
-
53
-
Number of sells
-
-40
-
Price
-
$1.32
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q3 2024
134 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q3 2024.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.4M shares
of 236M outstanding shares and own 25.16% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (15.2M shares), VANGUARD GROUP INC (10.1M shares), Alerce Investment Management, L.P. (5.75M shares), GEODE CAPITAL MANAGEMENT, LLC (4.75M shares), RENAISSANCE TECHNOLOGIES LLC (3.72M shares), STATE STREET CORP (3.43M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2.03M shares), NORTHERN TRUST CORP (1.64M shares), Qube Research & Technologies Ltd (1.32M shares), and MORGAN STANLEY (1.09M shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.